Navigate BioPharma Services announces a strategic collaboration with Becton, Dickinson and Company, BD, to explore opportunities to develop and commercialize flow cytometry-based companion diagnostics and tools for clinical decisions. The collaboration aims to leverage the complementary expertise and capabilities of both companies to provide end-to-end solutions for pharmaceutical and biotechnology companies developing novel therapies that require companion diagnostics, tests intended to match patients with life-changing treatments, and critical clinical trial applications that utilize flow cytometry. Importantly, this collaboration aims to address a critical gap in the clinical trial field for an integrated solution provider from method development to commercialization.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BDX:
- Becton Dickinson price target raised to $282 from $260 at Citi
- Jefferies healthcare analysts to hold an analyst/industry conference call
- Becton Dickinson price target raised to $303 from $284 at Barclays
- Becton Dickinson backs FY23 adjusted EPS view $12.10-$12.32, consensus $12.22
- Becton Dickinson reports Q3 adjusted EPS $2.96, consensus $2.91
